Purovitalis Liposomal NMN Capsules | 125mg
About Purovitalis Liposomal NMN Capsules | 125mg
Purovitalis Liposomal NMN Capsules - Exclusively Available In Pakistan | Enhances Cellular RepairPurovitalis Liposomal NMN Capsules contain 125 mg of high-purity Nicotinamide Mononucleotide (NMN) per serving, which is intended to improve cellular health, increase energy, and promote healthy aging. NAD+ (nicotinamide adenine dinucleotide), a key chemical that supports DNA repair, cellular metabolism, and general vitality, is strongly derived from NMN. This supplement is unique because it uses cutting-edge liposomal technology to encapsulate NMN in lipid layers for optimal absorption and bioavailability. This solves frequent absorption problems with conventional NMN supplements and enables a more efficient release of NMN into the bloodstream. Frequent usage of Purovitalis Liposomal NMN promotes cardiovascular health, enhances brain function, fights weariness, and slows down the aging process at the cellular level. Available In Pakistan
Who Should Use This?
- Improve cellular lifespan and counteract the effects of aging.
- Boost your energy levels both mentally and physically.
- Encourage general immunological and metabolic well-being
- Increase NAD+ levels to improve vigor.
Ingredients
Longevir™ NMN (β-Nicotinamide mononucleotide), lecithin (sunflower; emulsifier), Maltodextrin (bulking agent), HPMC (Vegan; capsule)
How to Use
Take 2 capsules daily. Best to take in the morning with breakfast.
Explore this product
Categories
Suggested use
Follow the manufacturer label. Ask a qualified healthcare professional when unsure.
Storage instructions
Store according to the manufacturer instructions and keep away from children.
Important warnings
Product information is educational and is not a substitute for professional medical advice. Consult a qualified healthcare professional before using supplements.
Verified customer reviews
No reviews yet. Verified buyers can share their delivery and product experience.
Questions and answers
No public questions answered yet.

